The inhibition of tumor growth by Bortezomib was associated with tumor necrosis and apoptosis, with the simultaneous inhibition of ErbB2, AKT, and with the induction of a strong intratumoral immune response. The gene discussed is ERBB2; the disease is neoplasm.